-
Akiva Diamond
Oncology / HematologyASH CLL Highlights - Promising Advances in Epcoritamab, TP53 Insights, and CHIP Findings - 7 month(s) agoHi everyone, I wanted to send one last email highlighting some of my favorite CLL abstracts from this year’s ASH meeting. First, I’d like to…
-
Akiva Diamond
Oncology / HematologyCLL 4 - 7 month(s) ago
-
Akiva Diamond
Oncology / HematologyCLL 4 - 7 month(s) ago
-
Akiva Diamond
Oncology / HematologyDear Colleagues, I hope everyone had a productive and enlightening experience at ASH—or at least got to enjoy following along on social media. I would…
-
Akiva Diamond
Oncology / HematologyASH Highlights: More Emerging Strategies in MRD-Directed CLL Therapy - 7 month(s) agoHi everyone, I’m excited to share more of my favorite CLL abstracts from this year’s ASH Annual Meeting. These studies emphasize innovative, MRD-guided approaches in…
-
Akiva Diamond
Oncology / HematologyASH CLL Highlights: Advances in MRD-Guided Therapy and QoL in CLL - 7 month(s) agoHi everyone, I’m excited to be back this year to share some of my favorite CLL abstracts from the ASH Annual Meeting. These abstracts highlight…
-
Akiva Diamond
Oncology / HematologyHi all, I’ve been reflecting on the great data presented at this year’s ASH Annual Meeting and Exposition and wanted to share some of my…
-
Akiva Diamond
Oncology / HematologyASH CLL Highlights - 2 year(s) ago
-
Akiva Diamond
Oncology / HematologyASH CLL Highlights - 2 year(s) ago
-
Akiva Diamond
Oncology / HematologyFocus on CLL at ASH 2023: New Approaches to Richter's - 2 year(s) agoHi all, As Day 4 of the ASH Annual Meeting and Exposition concludes, I’d like to revisit some key studies from the previous days. Highlights…